170 related articles for article (PubMed ID: 11248162)
21. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
Jiang ZF; Shao ZM; Xu BH
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
[No Abstract] [Full Text] [Related]
23. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
24. Trastuzumab trials steal show at ASCO meeting.
Tuma RS
J Natl Cancer Inst; 2005 Jun; 97(12):870-1. PubMed ID: 15956644
[No Abstract] [Full Text] [Related]
25. HER2-positive advanced breast cancer.
Robert NJ; Favret AM
Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450
[TBL] [Abstract][Full Text] [Related]
26. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].
Kitagawa D; Toi M
Nihon Rinsho; 2007 Jun; 65 Suppl 6():396-401. PubMed ID: 17682183
[No Abstract] [Full Text] [Related]
27. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Liao C; Yin F; Huang P; Cao Y; Gao F
Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
[No Abstract] [Full Text] [Related]
29. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response.
Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203
[No Abstract] [Full Text] [Related]
30. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
31. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
Roukos DH
J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
[No Abstract] [Full Text] [Related]
32. HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer.
Ziogas D; Ignatiadou E; Roukos D; Lykoudis E
Ann Surg Oncol; 2008 Dec; 15(12):3614-5; author reply 3616. PubMed ID: 18521683
[No Abstract] [Full Text] [Related]
33. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
34. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
Burstein HJ
Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
[TBL] [Abstract][Full Text] [Related]
35. Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).
Guarneri V; Frassoldati A; Piacentini F; Jovic G; Giovannelli S; Oliva C; Conte P
Clin Breast Cancer; 2008 Apr; 8(2):192-4. PubMed ID: 18621618
[No Abstract] [Full Text] [Related]
36. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
37. Herceptin: from the bench to the clinic.
Colomer R; Shamon LA; Tsai MS; Lupu R
Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
[No Abstract] [Full Text] [Related]
38. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
Wang LP; Shen KW; Shen ZZ
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
[No Abstract] [Full Text] [Related]
39. Overcoming treatment challenges in advanced breast cancer.
Harkins B; Geyer CE
Semin Oncol Nurs; 2007 Nov; 23(4 Suppl 2):S10-6. PubMed ID: 18054677
[TBL] [Abstract][Full Text] [Related]
40. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
